– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating petosemtamab monotherapy in 2/3L HNSCC, phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC, and phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC – Based on the Company's current operating plan, existing cash, cash equivalents, inclu ...

HAMILTON, Bermuda, Aug. 01, 2024 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. ("SiriusPoint" or the "Company") (NYSE:SPNT), an international specialty insurer and reinsurer, has announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on August 30, 2024 to Series B shareholders of record as of August 15, 2024. A ...

ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. The announcement will provide an operational update regarding the company's achievements during the quarter and will detail financial highlights. About Quoin Pharm ...

RUTLAND, Vt., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Casella Waste Systems, Inc. (NASDAQ: CWST), a regional solid waste, recycling and resource management services company, today reported its financial results for the three and six-month periods ended June 30, 2024. Key Highlights: Revenues were $377.2 million for the quarter, up $87.5 million, or up 30.2%, from the same period in 2023. Solid waste pricing for the quarter was up 5.7% from the same period in 2023, driven by 6.2% collection price growth and 4.8% d ...

CHANDLER, Ariz., Aug. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that its Board of Directors declared a quarterly cash dividend on its common stock of 45.4 cents per share. The dividend is payable on September 5, 2024, to stockholders of record on August 22, 2024. Microchip initiated quarterly cash dividend payments in the third quarter of fiscal year 2003 and has increased it ...

文章核心观点 - 两个Howard Hughes旗下的社区Summerlin和Bridgeland在2024年上半年销售表现出色,分别位列全美销量前5和前8的主规划社区[2] - 这反映了Howard Hughes社区提供的高品质生活方式和商业友好环境深受欢迎,公司预计2024年将创下住宅用地销售的历史新高[2] - 尽管面临高利率和房地产市场负面报道,但Howard Hughes社区仍保持强劲的年同比增长[2] Summerlin - Summerlin占地22,500英亩,是拉斯维加斯最受欢迎和销量最好的社区之一,为12.7万居民提供了无与伦比的自然环境和广泛的商业配套[3] - 当地就业市场增长速度是全国平均水平的两倍,吸引了大量科技公司、体育队和各行业企业家[3] - Summerlin提供了多样化的住房选择,从单户独立房到联排别墅不等,价格也有很大范围,这推动了大量住宅销售[3] - 2024年Summerlin预计将再创住宅用地销售新高,同时商业配套需求也保持强劲[3] Bridgeland - Bridgeland有望在2024年创造或超越2023年的年度销售记录,正在快速发展并改变休斯顿地区的城市格局[4] - 社区内有3,000多英亩的公园、湖泊和步道,以及优质学校和不断增加的就业机会,深受居民青睐[4] - 社区内包括Creekland Village、Parkland Village和Prairieland Village等多个住宅区,以及925英亩的Bridgeland Central城市区[4] - 休斯顿地区再次成为表现最佳的大都市区,在全美主规划社区销量排名中占据13席[4]

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm's current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, a ...

REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on June 1, 2024, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company ...

文章核心观点 - 公司第二季度收入为10亿美元,同比下降5.2% [4] - 公司第二季度营业利润为4000万美元,占收入的4.0% [6] - 公司通过股息支付和股票回购向股东返还了4800万美元 [9] - 公司预计2024年全年每股收益将在1.75美元至2.05美元之间 [10] 分组1: 财务表现 - 第二季度收入下降5.2%,主要受到运输市场疲软、中间运输和经纪业务收入下降的影响,但被中间运输业务量增长8%和最后一英里业务的贡献所抵消 [4] - 第二季度营业利润为4000万美元,占收入的4.0%,去年同期为6200万美元,占收入的6.0% [6] - 第二季度EBITDA(非GAAP)为8900万美元,净债务/EBITDA(非GAAP)为0.3倍 [6] - 中间运输和运输解决方案业务收入下降,利润下降 [7] - 物流业务收入增长,但利润下降 [8] 分组2: 资本运营 - 公司继续投资于车队、技术和仓储设施,第二季度资本支出为1400万美元 [9] - 截至6月30日,公司现金及现金等价物为2.2亿美元 [9] - 公司年初至今通过股息支付和股票回购向股东返还了4800万美元 [9] 分组3: 未来展望 - 公司预计2024年全年收入将在40亿至43亿美元之间,每股收益将在1.75美元至2.05美元之间 [10] - 公司预计全年资本支出将在4500万美元至6500万美元之间,税率约为24% [10]

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $27.3 million for the se ...